A detailed history of Acadian Asset Management LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 932,925 shares of AVIR stock, worth $2.98 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
932,925
Previous 934,505 0.17%
Holding current value
$2.98 Million
Previous $3.09 Million 1.0%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.17 - $4.02 $5,008 - $6,351
-1,580 Reduced 0.17%
932,925 $3.12 Million
Q2 2024

Aug 06, 2024

SELL
$3.31 - $4.04 $92,524 - $112,930
-27,953 Reduced 2.9%
934,505 $3.09 Million
Q4 2023

Feb 13, 2024

SELL
$2.8 - $3.35 $71,282 - $85,284
-25,458 Reduced 2.58%
962,458 $2.93 Million
Q3 2023

Nov 13, 2023

SELL
$3.0 - $3.79 $25,077 - $31,680
-8,359 Reduced 0.84%
987,916 $2.96 Million
Q2 2023

Aug 07, 2023

SELL
$3.21 - $5.06 $367,352 - $579,066
-114,440 Reduced 10.3%
996,275 $3.72 Million
Q1 2023

May 11, 2023

BUY
$3.0 - $4.97 $727,395 - $1.21 Million
242,465 Added 27.93%
1,110,715 $3.72 Million
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $184,818 - $262,144
42,487 Added 5.15%
868,250 $4.17 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $611,262 - $978,687
111,341 Added 15.58%
825,763 $4.7 Million
Q2 2022

Aug 09, 2022

SELL
$5.33 - $8.18 $736,360 - $1.13 Million
-138,154 Reduced 16.2%
714,422 $5.07 Million
Q1 2022

May 12, 2022

BUY
$5.5 - $9.19 $3.19 Million - $5.33 Million
580,315 Added 213.15%
852,576 $6.15 Million
Q4 2021

Feb 10, 2022

BUY
$7.67 - $44.59 $1.86 Million - $10.8 Million
241,916 Added 797.22%
272,261 $2.43 Million
Q3 2021

Nov 12, 2021

SELL
$21.33 - $35.06 $71,860 - $118,117
-3,369 Reduced 9.99%
30,345 $1.06 Million
Q2 2021

Aug 11, 2021

BUY
$19.22 - $59.08 $647,983 - $1.99 Million
33,714 New
33,714 $724,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.